Question 1

How do DPP-4 inhibitors work to lower blood glucose levels?

Accepted Answer

DPP-4 inhibitors bind to dipeptidyl peptidase 4, blocking the inactivation of GLP-1 and GIP hormones. This increases active hormone levels, which enhances insulin secretion and reduces glucagon, improving glucose homeostasis pancreatic islets and insulin secretion. The result is better control of fasting and postprandial hyperglycemia without affecting insulin sensitivity or gastric motility.

Question 2

What are the common DPP-4 inhibitor medications used in diabetes treatment?

Accepted Answer

Common DPP-4 inhibitors include sitagliptin, saxagliptin, linagliptin, alogliptin, and vildagliptin. These gliptins are available at varying standard doses: sitagliptin at 100 mg, saxagliptin and linagliptin at 5 mg, alogliptin at 25 mg, and vildagliptin at 50 mg once or twice daily. Each medication offers similar efficacy in reducing A1c levels.

Question 3

How effective are DPP-4 inhibitors at reducing A1c levels?

Accepted Answer

When used alone, DPP-4 inhibitors reduce A1c levels by approximately 0.8% on average. When combined with other hypoglycemic agents, they achieve greater reductions of about 1.3% total A1c decrease. This combination approach provides enhanced glycemic control for patients requiring more aggressive management.

Question 4

What are the key differences in how DPP-4 inhibitors are metabolized?

Accepted Answer

Most DPP-4 inhibitors are absorbed from the small intestine and excreted unchanged in urine, requiring dose adjustment in renal impairment. Linagliptin undergoes extensive plasma protein binding and hepatobiliary clearance. Saxagliptin is metabolized by hepatic microsomal enzymes and requires dosage adjustment when combined with strong CYP3A4 inhibitors.

Question 5

What adverse effects should clinicians monitor with DPP-4 inhibitor use?

Accepted Answer

DPP-4 inhibitors are generally well tolerated with rare adverse effects. However, the FDA warns of severe joint pain and pancreatitis. Saxagliptin carries an increased risk of hospitalizations for heart failure, requiring careful patient selection and monitoring in individuals with cardiovascular risk factors or heart failure history.

Question 6

Why might DPP-4 inhibitors require dose adjustments in certain patient populations?

Accepted Answer

Most DPP-4 inhibitors are excreted unchanged in urine, so lower doses are necessary for patients with reduced renal function. Saxagliptin requires dosage adjustment when coadministered with strong CYP3A4 inhibitors due to hepatic metabolism. These adjustments prevent drug accumulation and maintain therapeutic safety.

Question 7

How do DPP-4 inhibitors compare to other oral hypoglycemic agents in their mechanism?

Accepted Answer

Unlike oral hypoglycemic agents biguanides and glitazones that improve insulin sensitivity, DPP-4 inhibitors work by preserving active incretin hormones. They enhance insulin secretion and reduce glucagon without directly affecting insulin sensitivity, gastric motility, or satiety, offering a distinct pharmacological approach to glucose regulation.

Dipeptidyl Peptidase 4 Inhibitors

Browse More Videos